Overview

Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy

Status:
Completed

Trial end date:
2006-11-01

Target enrollment:

Participant gender:

Summary

A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up.

Phase:

Phase 2

Details

Lead Sponsor:

UCB Pharma

Treatments:

Certolizumab Pegol